Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study

The cost-effectiveness of Cerebrolysin as an add-on therapy for moderate–severe acute ischemic stroke is a topic that remains understudied. This study aims to address this gap by performing a comprehensive cost-utility analysis using both deterministic and probabilistic methods from a payer perspect...

Descripción completa

Detalles Bibliográficos
Autores principales: Strilciuc, Stefan, Radu, Constantin, Grad, Diana-Alecsandra, Stan, Adina Dora, Vladescu, Cristian, Buzoianu, Anca Dana, Muresanu, Dafin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218347/
https://www.ncbi.nlm.nih.gov/pubmed/37239783
http://dx.doi.org/10.3390/healthcare11101497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218347/
https://www.ncbi.nlm.nih.gov/pubmed/37239783
http://dx.doi.org/10.3390/healthcare11101497

Ejemplares similares